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Abstract: Naturally occurring nucleoside-peptide antibiotics such as muraymycins or caprazamycins
are of major interest for the development of novel antibacterial agents. However, the synthesis of new
analogues of these natural products for structure–activity relationship (SAR) studies is challenging.
In our synthetic efforts towards a muraymycin-derived nucleoside building block suitable for
attachment to a solid support, we came across an interesting side product. This compound resulted
from an undesired Fmoc deprotection with subsequent cyclization, thus furnishing a remarkable
caprazamycin-like seven-membered diazepanone ring.
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1. Introduction
Emerging bacterial strains that are resistant to antibiotics are a severe threat in healthcare [1–3].
To address this problem, novel antibacterial agents with previously unexploited modes of action are
urgently needed [4]. A promising class that meets this requirement are uridine-derived nucleoside-
peptide antibiotics that interfere with bacterial cell wall biosynthesis [5–7]. They inhibit MraY,
an enzyme that catalyzes a membrane-associated step in the intracellular part of peptidoglycan
formation [8–13]. Among this structurally diverse class, our research focusses mainly on the subclasses
of muraymycins [14,15] and caprazamycins [16–22] (Figure 1). For muraymycins, a co-crystal
structure in complex with MraY has been reported, enabling deeper insights into the inhibitor-target
interaction [23–25]. However, experimental structure–activity relationship (SAR) studies are still
crucial due to the pronounced conformational plasticity of MraY, and have therefore been carried out
extensively as exemplified by the according work on muraymycins [26–35].
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Figure 1. Structures of the nucleoside-peptide antibiotics muraymycins and caprazamycins. 
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simplified muraymycin analogues [36]. This novel strategy was based on the stepwise construction of
the muraymycin peptide unit on the solid support. As part of our initial studies on this approach, we
had also investigated a potential attachment of the muraymycin nucleoside unit (or an analogue thereof)
to the solid phase. Hence, we had envisioned to prepare uridine-derived building block 5 (see Scheme 2)
that could then be connected to the solid phase. The design of 5 was based on our previously reported
strategy to simplify the muraymycin core structure by omission of the 5′-substituent (“5′-deoxy”
analogues) [30,33,35–38]. Carboxylic acid 5 was intended to be attached to a trityl resin by formation
of a trityl ester. In order to then apply standard solid-phase protocols for the assembly of the peptide
unit, we chose Fmoc as protecting group for the terminal amino group of the linker moiety. For the
preparation of 5, we intended to selectively cleave the tert-butyl ester in the 7′-position of precursor
4 (Schemes 1 and 2). Studies on this particular transformation have furnished the unexpected side
reaction reported in this work.
2. Results
The synthesis of the fully protected uridine-derived precursor building block 4 involved protocols
that were previously reported by our group. Thus, uridine 1 was transformed into the protected
nucleosyl amino acid 2 using an established five-step route (Scheme 1) [30,37,38]. This was followed
by reductive amination of 2 with Fmoc-protected aldehyde 3 [36]. The reductive amination step
was carried out in a similar way as with other Cbz-protected aldehydes as previously reported [30]
(i.e., using amberlyst as acidic activator and sodium triacetoxyborohydride as reducing agent). The
resultant product 4 was obtained in 71% yield (Scheme 1).
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product 6 (without the Fmoc protecting group) in a yield of 41% (Table 1, entry 1). This was 
unexpected, as the Fmoc group usually requires basic conditions for its cleavage. We speculated 
that, under the applied reaction conditions (high temperature, extended reaction period of 5 days), 
the secondary amine at the 6′-position of 4 might have been sufficiently basic to mediate Fmoc 
deprotection. The resultant primary amine then probably attacked the 7′-tert-butyl ester of 4, thus 
leading to ring formation (proposed mechanism not shown). By significantly decreasing the reaction 
period, the yield of side product 6 even increased to 68% (after 1.5 days, Table 1, entry 2) and 76% 
(after 5 h, entry 3), respectively. This demonstrated that 6 was indeed the main product of this 
transformation at elevated temperatures. Variation of the temperature then revealed that the desired 
product 5 might have been formed at lower temperatures, but only in small amounts. Target 
compound 5 was obtained when the reaction mixture was stirred at 80 °C for 1 day and then at room 
temperature (rt) for further 2 days, furnishing a moderate yield of 48% of 5 (Table 1, entry 4). Further 
attempts to repeat this reaction towards 5 and possibly improve its yield only gave worse results 
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therefore studied the mild acidic cleavage of the tert-butyl ester of 4—as previously reported by us for
similar transformations [39]—in order to potentially obtain 5 (Scheme 2). In first attempts, the reaction
was carried out by stirring a solution of 4 in toluene in the presence of silica at reflux temperature
(i.e., 111 ◦C (Table 1, entries 1–3)). The conversion of 4 was monitored by thin layer chromatography
(TLC). Surprisingly, a seven-membered diazepanone ring was formed to give main product 6 (without
the Fmoc protecting group) in a yield of 41% (Table 1, entry 1). This was unexpected, as the Fmoc
group usually requires basic conditions for its cleavage. We speculated that, under the applied
reaction conditions (high temperature, extended reaction period of 5 days), the secondary amine at the
6′-position of 4 might have been sufficiently basic to mediate Fmoc deprotection. The resultant primary
amine then probably attacked the 7′-tert-butyl ester of 4, thus leading to ring formation (proposed
mechanism not shown). By significantly decreasing the reaction period, the yield of side product 6
even increased to 68% (after 1.5 days, Table 1, entry 2) and 76% (after 5 h, entry 3), respectively. This
demonstrated that 6 was indeed the main product of this transformation at elevated temperatures.
Variation of the temperature then revealed that the desired product 5 might have been formed at
lower temperatures, but only in s all amounts. Target compound 5 was obtained when the reaction
mixture was stirred at 80 ◦C for 1 day and then at room temperature (rt) for further 2 days, furnishing
a oderate yield of 48% of 5 (Table 1, entry 4). Further attempts to repeat this reaction towards 5
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and possibly improve its yield only gave worse results (i.e., lower yields with significant amounts of
unidentified impurities). We also explored other conditions to selectively cleave the tert-butyl ester,
mainly the treatment of 4 with TFA (Table 1, entries 5–7) or with pig liver esterase (PLE, entry 8), but
none of these experiments afforded satisfying conversions to the desired carboxylic acid 5.
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Table 1. Investigated conditions for the attempted reaction of 4 to 5 (see Scheme 2).
# Reagents Te perature Reaction Period Product
1 SiO2, toluene 111 ◦ flux) ays 41% 6
2 SiO2, toluene 111 ◦C (reflux) 1.5 days 68% 6
3 SiO2, toluene 111 ◦C (reflux) 5 h 76% 6
4 SiO2, toluene 80 ◦C, then rt 3 days 48% 5
5 80% TFA/CH2Cl2 rt 2 h
partial TBDMS
deprotection
6 80% TFA/CH2Cl2 rt 1 h
16% 5
(24% brsm 1)
7 50% TFA/CH2Cl2 rt 2.5 h full TBDMS deprotection
8 PLE, phosphate buffer (pH 7.5,0.1 M), DMF rt 2 days no reaction
1 brsm = based on recovered starting material.
Since no reaction conditions were identified that gave the desired uridine-derived building block
5 in robust, reproducible and sati fying yields, this strategy for the solid phase-supported synthesis of
muraymycin analogues was discarded, and our reported route (vide supra) was established instead [36].
The obtained diazepa one side product 6 represented an interesting structure as it strongly resembles
the core struct re (“caprazol”) of caprazamycin antibiotics (cf. Figure 1). We therefore intended to
evaluate a deprotected derivative of 6 for its biological activity. Uridine- erived diazepanone 6 as
globally deprotected using 80% aqueous TFA for acidic desilylation (Scheme 2). The resultant fully
deprotected caprazol analogue 7 was purified by semipreparative HPLC. In the 1H NMR spectrum of
the obtained product, two sets of signals for the H-5 and H-6 protons of the nucleobase were observed,
hinting at a uracil-derived impurity that could not be separated from target compound 7 and that
could not be identified. However, the amount of this impurity could be estimated from the 1H NMR to
be ~30% based on the uracil-associated signals. We therefore decided to test this mixture of 7 and the
unidentified impurity for its potential to inhibit the bacterial target protein MraY, using an established
in vitro assay for MraY activity [32,33,40]. It was found that the IC50 value of the mixture containing
caprazol analogue 7 was outside of the relevant range (IC50 > 50 µg/mL), thus demonstrating that 7 did
not inhibit MraY to a relevant extent (also see Supplementary Materials, Figure S1, for measured data).
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3. Discussion
The encountered side reaction from precursor 4 to diazepanone 6 is highly interesting as the
construction of the diazepanone scaffold represents one of the main challenges in the total synthesis of
caprazamycins and their analogues [18,19,21,22]. To the best of our knowledge, a simple thermally
promoted nucleophilic attack of the linker unit to a 7′-carboxylic acid ester moiety has not been
successfully explored for the diazepanone-forming step before. The good yields of 6 obtained from this
reaction strongly suggest that it should be investigated for caprazamycin syntheses in a more systematic
way in the future. Additionally, it has not escaped our notion that this transformation might even be
considered to be “biomimetic” with respect to the proposed biosynthesis of caprazamycins [41,42].
However, it seems possible that a cyclization precursor decorated with more functional groups
(i.e., an analogue of 4 closer resembling a non-simplified caprazamycin precursor) might undergo
decomposition reactions at the elevated temperatures needed for diazepanone formation. Such hurdles
might be overcome by the choice of more reactive (i.e., less bulky) ester units in the 7′-position, thus
potentially allowing lower temperatures for the ring closure reaction after Fmoc deprotection.
The missing inhibitory potential of the deprotected uridine-derived diazepanone 7 towards MraY
shows that a simplified 5′-defunctionalized (“5′-deoxy”) version of the caprazamycin core structure
(“caprazol”) does not inhibit this bacterial target protein, at least not in the relevant concentration
range. This supports the conclusion that at least some of the functionalized side chain structures found
in caprazamycins (cf. Figure 1) are relevant for biological activity.
In summary, we report an interesting and unexpected formation of a caprazamycin-like
seven-membered diazepanone ring in a supposedly facile ester cleavage en route to muraymycin
analogues. It is particularly remarkable that this side product was obtained in yields much higher
than those of the desired product. Additionally, the complete cleavage of the Fmoc group under the
(supposedly slightly acidic) reaction conditions was surprising. The observed side reaction might pave
the way for the development of more efficient strategies for diazepanone formation in the synthesis of
caprazamycin analogues.
4. Materials and Methods
4.1. Synthesis
General methods: All chemicals were purchased from standard suppliers and used without
further purification. Reactions involving oxygen and/or moisture sensitive reagents were carried out
under an atmosphere of nitrogen using anhydrous solvents. Anhydrous solvents were obtained in
the following manner: THF was dried with a solvent purification system (MBRAUN MB SPS 800,
M. Braun, Garching, Germany). All other solvents were of technical quality and distilled prior to
use, and deionized water was used throughout. Analytical TLC was performed on aluminum plates
precoated with silica gel 60 F254 (VWR, Darmstadt, Germany). Visualization of the spots was carried
out using UV light (254 nm) and/or staining under heating (H2SO4 staining solution: 4 g vanillin, 25 mL
conc. H2SO4, 80 mL AcOH and 680 mL MeOH; KMnO4 staining solution: 1 g KMnO4, 6 g K2CO3
and 1.5 mL 1.25 m NaOH solution, all dissolved in 100 mL H2O; ninhydrin staining solution: 0.3 g
ninhydrin, 3 mL AcOH and 100 mL 1-butanol). Preparative TLC was carried out on a ChromatotronTM
7924T by T-Squared Technology (San Bruno/CA, USA), using glass plates coated with silica gel 60
PF254 containing a fluorescent indicator (VWR, Darmstadt, Germany; thickness depending on the
amount of crude material to be separated, for 50–500 mg: 1 mm layer). Column chromatography
was carried out on silica gel 60 (0.040–0.063 mm, 230–400 mesh ASTM, VWR, Darmstadt, Germany)
under flash conditions. Semipreparative HPLC was performed on an Agilent Technologies 1200 Series
system equipped with an MWD detector (254/280) (Agilent Trechnologies, Waldbronn, Germany)
and a LiChroCartTM column (10 × 250 mm) containing reversed phase silica gel PurospherTM RP18e
(5 µm, VWR, Darmstadt, Germany). Method: eluent A water, eluent B MeCN; 0–35 min gradient of B
(10%–100%), 35–39 min 100% B, 39–40 min gradient of B (100%–10%), 40–45 min 10% B; flow 3 mL/min.
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500 MHz-1H, 126 MHz-13C, and 376 MHz-19F NMR spectra were recorded on Bruker AVANCE-500
spectrometers (Bruker, Bremen, Germany). All 13C and 19F NMR spectra were 1H-decoupled. All
spectra were recorded at room temperature and were referenced internally to solvent reference
frequencies wherever possible. Chemical shifts (δ) are given in ppm and coupling constants (J) are
reported in Hz. Assignment of signals was carried out using 1H,1H-COSY, HSQC and HMBC spectra.
High-resolution ESI mass spectra were measured on a Dionex UltiMate 3000 HPLC system and on a
Bruker time-of-flight (TOF) maXis (Bruker, Bremen, Germany). Infrared spectra (IR) were measured
on a Bruker Vertex 70 spectrometer equipped with an integrated ATR unit (PlatinumATRTM, Bruker,
Bremen, Germany). Wavenumbers (υ̃) are quoted in cm–1. UV spectra were measured on an Agilent
Cary 100 spectrophotometer (Agilent Trechnologies, Waldbronn, Germany). Wavelengths of maximum
absorption (λmax) are reported in nm.
N-Fmoc-protected aminoalkylated uridinyl amino acid tert-butyl ester (4): Protected nucleosyl
amino acid 2 [30,37,38] (98.0 mg, 0.167 mmol) was dissolved in THF (6 mL) over molecular sieves (4 Å).
N-Fmoc-protected aldehyde 3 [36] (75.0 mg, 0.254 mmol) was added and the mixture was stirred at rt
for 21 h. Amberlyst™ (7.9 mg, 37 µmol) and sodium triacetoxyborohydride (75.7 mg, 0.357 mmol) were
added and the solution was stirred at rt for further 24 h. The reaction mixture was then filtered, and the
molecular sieves were washed with EtOAc. The combined filtrates were washed with saturated (sat.)
Na2CO3 solution (50 mL) and the aqueous layer was extracted with EtOAc (50 mL). The organic layer
was dried over Na2SO4 and the solvent was evaporated under reduced pressure. The resultant crude
product was purified by column chromatography (100:0→ 99:1→ 98:2, CH2Cl2–MeOH) to give 4 as a
colorless foam (102 mg, 71%). 1H NMR (500 MHz, CDCl3): δ [ppm] = 0.07 (s, 3H, SiCH3), 0.07 (s, 3H,
SiCH3), 0.07 (s, 3H, SiCH3), 0.09 (s, 3H, SiCH3), 0.88 (s, 9H, SiC(CH3)3), 0.90 (s, 9H, SiC(CH3)3), 1.47 (s,
9H, OC(CH3)3), 1.65–1.71 (m, 2H, 2′′-H), 1.83–1.89 (m, 1H, 5′-Ha), 1.98–2.02 (m, 1H, 5′-Hb), 2.54–2.59
(m, 1H, 1′′-Ha), 2.70–2.75 (m, 1H, 1′′-Hb), 3.24–3.35 (m, 3H, 3′′-H, 6′-H), 3.66–3.68 (m, 1H, 3′-H),
4.10–4.14 (m, 1H, 4′-H), 4.20–4.25 (m, 2H, 2′-H, Fmoc-9-H), 4.33–4.42 (m, 2H, Fmoc-CH2), 5.41–5.44
(m, 1H, 3′′-NH), 5.59 (s, 1H, 1′-H), 5.71 (d, J = 8.2 Hz, 1H, 5-H), 7.29 (t, J = 7.4 Hz, 2H, Fmoc-3-H,
Fmoc-6-H), 7.34 (d, J = 8.2 Hz, 1H, 6-H), 7.38 (t, J = 7.4 Hz, 2H, Fmoc-2-H, Fmoc-7-H), 7.59 (d, J =
7.4 Hz, 2H, Fmoc-4-H, Fmoc-5-H), 7.75 (d, J = 7.4 Hz, 2H, Fmoc-1-H, Fmoc-8-H). 13C NMR (126 MHz,
CDCl3): δ [ppm] = −4.74 (SiCH3), −4.67 (SiCH3), −4.44 (SiCH3), −4.02 (SiCH3), 18.08 (SiC(CH3)3), 18.18
(SiC(CH3)3), 25.88 (SiC(CH3)3), 25.95 (SiC(CH3)3), 28.21 (OC(CH3)3), 29.90 (C-2′′), 37.36 (C-5′), 39.30
(C-3′′), 45.67 (C-1′′), 47.38 (Fmoc-C-9), 60.03 (C-6′), 66.72 (Fmoc-CH2), 74.87 (C-2′), 75.39 (C-3′), 81.08
(C-4′), 81.93 (OC(CH3)3), 92.41 (C-1′), 102.32 (C-5), 120.07 (Fmoc-C-1, Fmoc-C-8), 125.21 (Fmoc-C-4,
Fmoc-C-5), 127.11 (Fmoc-C-3, Fmoc-C-6), 127.75 (Fmoc-C-2, Fmoc-C-7), 140.53 (C-6), 141.40 (Fmoc-C-1a,
Fmoc-C-8a), 144.12 (Fmoc-C-4a, Fmoc-C-5a), 150.07 (C-2), 156.61 (urea-C=O), 163.22 (C-4), 173.96 (C-7′).
HRMS (ESI): calcd. for C45H69N4O9Si2: 865.4598 [M + H]+, found 865.4608. IR (ATR): υ̃ = 2929, 2856,
1687, 1450, 1251, 1151, 836, 776, 739. UV (CHCl3): λmax = 266, 301. optical rotation: α20D = +90.0 (c = 1.0,
CHCl3). TLC: Rf = 0.20 (19:1, CH2Cl2–MeOH).
N-Fmoc-protected aminoalkylated uridinyl amino acid (5): N-Fmoc-protected aminoalkylated
uridinyl amino acid tert-butyl ester 4 (54.4 mg, 62.9 µmol) was dissolved in toluene (10 mL). Silica
(409 mg) was added, the reaction mixture was heated to 80 ◦C and stirred at this temperature for
1 day. Then, the mixture was allowed to cool to rt and stirred at rt for further 2 days. The mixture
was filtered, the silica was washed with a mixture of CH2Cl2 and MeOH (1:1), and the solvent of the
combined filtrates was evaporated under reduced pressure. The resultant crude product was purified
by preparative TLC (chromatotron, 9:1→ 4:1, CH2Cl2–MeOH) to give 5 as a yellowish solid (24.6 mg,
48%). 1H NMR (500 MHz, CDCl3): δ [ppm] = −0.13 (s, 3H, SiCH3), −0.01 (s, 3H, SiCH3), 0.07 (s, 6H,
SiCH3), 0.81 (s, 9H, SiC(CH3)3), 0.89 (s, 9H, SiC(CH3)3), 1.78–1.94 (m, 2H, 2′′-H), 2.03–2.33 (m, 2H,
5′-H), 3.02–4.53 (m, 11H, 1′′-H, 3′′-H, 6′-H, 2′-H, 3′-H, 4′-H, Fmoc-9-H, Fmoc-CH2), 5.02–5.19 (m, 2H,
1′-H, 3′′-NH), 5.55–5.71 (m, 1H, 5-H), 7.26–7.29 (m, 2H, Fmoc-3-H, Fmoc-6-H), 7.33–7.37 (m, 3H, 6-H,
Fmoc-2-H, Fmoc-7-H), 7.51–7.62 (m, 2H, Fmoc-4-H, Fmoc-5-H), 7.72 (d, J = 7.7 Hz, 2H, Fmoc-1-H,
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Fmoc-8-H). MS (ESI): m/z = 809.51 [M + H]+. HRMS (ESI): calcd. for C41H61N4O9Si2: 809.3972 [M +
H]+, found 809.3949. TLC: Rf = 0.18 (9:1, CH2Cl2–MeOH).
Protected uridine-derived diazepanone (6): N-Fmoc-protected aminoalkylated uridinyl amino
acid tert-butyl ester 4 (63.1 mg, 49.8 µmol) was dissolved in toluene (8 mL). Silica (208 mg) was added
and the reaction mixture was stirred under reflux for 1.5 days. Then, the mixture was allowed to cool to
rt and the solvent was evaporated under reduced pressure. The resultant crude product was purified
by column chromatography (95:5→ 9:1→ 4:1, CH2Cl2–MeOH) to give 6 as a colorless oil (19.3 mg,
68%). 1H NMR (500 MHz, CD3OD): δ [ppm] = 0.04 (s, 3H, SiCH3), 0.09 (s, 3H, SiCH3), 0.13 (s, 3H,
SiCH3), 0.16 (s, 3H, SiCH3), 0.89 (s, 9H, SiC(CH3)3), 0.94 (s, 9H, SiC(CH3)3), 1.57–1.66 (m, 1H, 2′′-Ha),
1.71–1.77 (m, 2H, 2′′-Hb, 5′-Ha), 2.32–2.37 (m, 1H, 5′-Hb), 2.90–2.95 (m, 1H, 1′′-Ha), 3.23–3.27 (m, 2H,
1′′-Hb, 3′′-Ha), 3.35–3.42 (m, 1H, 3′′-Hb), 3.55 (dd, J = 8.2, 5.3 Hz, 1H, 6′-H), 3.99 (dd, J = 4.4, 3.3 Hz, 1H,
3′-H), 4.13 (ddd, J = 10.6, 3.3, 3.3 Hz, 1H, 4′-H), 4.40 (dd, J = 5.9, 4.4 Hz, 1H, 2′-H), 5.77 (d, J = 8.1 Hz, 1H,
5-H), 5.84 (d, J = 5.9 Hz, 1H, 1′-H), 7.67 (d, J = 8.1 Hz, 1 H, 6-H). 13C NMR (126 MHz, CD3OD): δ [ppm]
= −4.64 (SiCH3), −4.38 (SiCH3), −4.35 (SiCH3), −4.17 (SiCH3), 18.87 (SiC(CH3)3), 18.97 (SiC(CH3)3),
26.34 (SiC(CH3)3), 26.42 (SiC(CH3)3), 31.43 (C-2′′), 36.99 (C-5′), 41.99 (C-3′′), 51.58 (C-1′′), 58.68 (C-6′),
75.35 (C-2′), 77.09 (C-3′), 84.67 (C-4′), 91.31 (C-1′), 103.23 (C-5), 143.12 (C-6), 152.28 (C-2), 165.97 (C-4),
178.69 (C-7′). MS (ESI): m/z = 569.33 [M + H]+. HRMS (ESI): calcd. for C26H49N4O6Si2: 569.3185 [M +
H]+, found 569.3177. IR (ATR): υ̃ = 2920, 2851, 1738, 1457, 1374, 1229, 1070, 797. UV (CHCl3): λmax =
224. TLC: Rf = 0.24 (9:1, CH2Cl2–MeOH).
Uridine-derived diazepanone (7): Protected uridine-derived diazepanone 6 (6.1 mg, 10.7 µmol)
was dissolved in TFA (80% in water, 3 mL). The reaction mixture was stirred at rt for 24 h and the solvent
was evaporated under reduced pressure. The resultant crude product was purified by semipreparative
HPLC to give 7 (TFA salt) as a colorless solid (2.0 mg containing ~30% of an unknown uracil-derived
impurity; 100% yield: 4.9 mg). 1H NMR (500 MHz, D2O): δ [ppm] = 1.77–1.85 (m, 1H, 2′′-Ha), 1.94–2.05
(m, 2H, 5′-Ha, 2′′-Hb), 2.50–2.55 (m, 1H, 5′-Hb), 3.22–3.27 (m, 1H, 3′′-Ha), 3.35–3.37 (m, 1H, 1′′-Ha),
3.47–3.52 (m, 2H, 1′′-Hb, 3′′-Hb), 4.07–4.11 (m, 2H, 3′-H, 4′-H), 4.14–4.17 (m, 1H, 6′-H), 4.43 (dd, J =
5.0, 3.9 Hz, 1H, 2′-H), 5.71 (d, J = 3.9 Hz, 1H, 1′-H), 5.76 (d, J = 7.7 Hz, 1H, unknown, probably 5-H),
5.86 (d, J = 8.1 Hz, 1 H, 5-H), 7.50 (d, J = 7.6 Hz, 1 H, unknown, probably 6-H), 7.63 (d, J = 8.1 Hz, 1H,
6-H). 13C NMR (126 MHz, D2O): δ [ppm] = 26.70 (C-2′′), 32.73 (C-5′), 39.77 (C-3′′), 48.83 (C-1′′), 56.78
(C-6′), 72.66 (C-2′), 73.15 (C-3′), 80.67 (C-4′), 91.97 (C-1′), 101.10 (unknown, probably C-5), 102.34 (C-5),
142.95 (C-6), 143.47 (unknown, probably C-6), 151.52 (C-2), 166.31 (C-4), 173.19 (C-7′). 19F NMR (376
MHz, D2O): −75.69 (TFA-CF3). MS (ESI): m/z = 341.11 [M + H]+. HRMS (ESI): calcd. for C14H21N4O6:
341.1456 [M + H]+, found 341.1448. UV (H2O): λmax = 202, 260. HPLC: tR = 8.4 min.
4.2. Overexpression of MraY from S. aureus
The overexpression of MraY was performed as described before [32,33,40].
4.3. Fluorescence-Based MraY Assay
The MraY assay was performed as described before [32,33,40]. Measured data are shown in the
Supplementary Materials, Figure S1.
Supplementary Materials: The following are available online, data from the MraY assays, copies of NMR and
IR spectra.
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